Mead Johnson Nutrition Company (MJN) retreated with the stock falling -0.18% or $-0.16 to close at $88.04 on active trading volume of 7.87M compared its three months average trading volume of 3.06M. The Glenview Illinois 60026 based company operating under the Processed & Packaged Goods industry has been trending up for the last 52 weeks, with the shares price now 23.31% up for the period and up by 24.42% so far this year. With price target of $81.7 and a 27.13% rebound from 52-week low, Mead Johnson Nutrition Company has plenty of upside potential, making it a hold with a view buy.
Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. It offers routine infant formula products as a breast milk substitute for healthy infants for use as the infant’s source of nutrition, as well as a supplement to breastfeeding under the Enfamil Premium, Enfapro Premium, Enfalac A+, and Enfamil A+ names; and solutions products to address common feeding tolerance problems, including spit-up, fussiness, gas, and lactose intolerance under the Enfamil Gentlease, Enfamil A.R., Enfamil ProSobee, and Enfamil LactoFree names. The company also provides specialty formula products, including formulas for addressing special medical needs, such as Nutramigen for cow’s milk protein allergies, as well as Puramino, an amino acid formula for cow’s milk protein allergies or multiple other food allergies; Enfamil Premature to meet the needs of premature and low birth weight infants; EnfaCare, a hypercaloric formula for premature babies at home; and produces medical foods for nutritional management of individuals with rare, inborn errors of metabolism comprising maple syrup urine disease and phenylketonuria. In addition, it offers children’s nutrition products comprising products for meeting children’s nutritional needs at toddlers and older children stage, as well as offer milk modifiers under the Enfagrow, Sustagen, Lactum, ChocoMilk, and Cal-C-Tose names; a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers under the Expecta and EnfaMama names; and pediatric vitamin products under the Enfamil Poly-Vi-Sol name, as well as multivitamins and iron supplements for infants. The company sells its products to mothers, health care professionals, and retailers in approximately 50 countries in Asia, North America, Latin America, and Europe. Mead Johnson Nutrition Company was founded in 1905 and is headquartered in Glenview, Illinois.
Pfizer Inc. (PFE) gained $0.14 to close the day at a new closing price of $32.75, a 0.43% increase in value from its previous closing price that moved the stock 18.28% above its 52 week low of $28.74. A total of 22.89M shares exchanged hands during the day compared with its three month average trading volume of 24.94M. The stock, which fluctuated between $32.35 and $32.77 during the day, currently situated -9.89% below its 52 week high. The stock is up by 1.73% in the past one month and up by 1.51% over the past three months. With a one year target estimate of $37.48 and RSI of 65, the stock still has upside potential, making it a hold for now.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Nielsen Holdings plc (NLSN) shares were down in last trading by -0.47% to $44.77. It experienced higher than average volume on day. The stock increased in value by almost 6.95% over the past week and grew 5.69% in the past month. It is currently trading 6.05% above its 50 day moving average and -8.19% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -18.93% decrease in value from its one year high of $55.94. The RSI indicator value of 71.11, lead us to believe that it may reverse gains in the near term.
Nielsen Holdings plc operates as an information and measurement company. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch and listen. Its Buy segment provides retail transactional measurement data, consumer behavior information, and analytics primarily to businesses in the consumer packaged goods industry. This segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in development and marketing cycles. The company’s Watch segment provides viewership and listening data, and analytics primarily to the media and advertising industries for television, radio, digital and mobile viewing, and listening platforms. It offers television audience measurement services, including more than one screen, unduplicated reach, cause and effect analysis, and program viewing behavior testing; audio audience measurement services; digital audience measurement services, such as digital media and market research, audience analytics, and social media measurement; mobile measurement services comprising measurement and consumer research for telecom and media companies; and advertiser solutions. The company was formerly known as Nielsen N.V. and changed its name to Nielsen Holdings plc in August 2015. The company was founded in 1923 and is headquartered in Oxford, the United Kingdom.